News | November 09, 2023
Biocon Biologics announces divestment of two non-core branded formulations
Total transaction value of the divestment is Rs. 3,660 million
Total transaction value of the divestment is Rs. 3,660 million
This project will aim to develop a next-generation A3 adenosine receptor drug agonists
Zydus will pay an upfront consideration of GBP 68 million and yearly earn-outs until 2026
Aster Whitefield will be Aster's 3 rd multi-specialty hospital in Bengaluru and overall 19th hospital in India
Additional premium services in RegXcellence will include access to BASF’s Product Carbon Footprint data and direct downloads of audit reports
The vaccine further advances Pfizer’s vaccine portfolio and builds on more than 20 years of expertise and knowledge in the prevention of meningococcal disease
Approval of oral, once-daily VELSIPITY based on favorable safety and efficacy data from the ELEVATE UC Phase 3 trials
Seamless transition from preclinical to first-in-human trials with EUDRACAP platform technology
Profit after tax (before exceptional items) up 23% to Rs 215 crores
NexCAR19 is an indigenously developed CD19 targeted CAR-T cell therapy
Subscribe To Our Newsletter & Stay Updated
